Please login to the form below

Not currently logged in
Email:
Password:

Ignyta

This page shows the latest Ignyta news and features for those working in and with pharma, biotech and healthcare.

Roche buys cancer company Ignyta for $1.7bn

Roche buys cancer company Ignyta for $1.7bn

Roche buys cancer company Ignyta for $1.7bn. Pursues same oncology target that encouraged Bayer's recent deal with Loxo. ... Once the deal goes through, Ignyta will continue to run the pivotal trial of entrectinib from its current base in San Diego.

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals in March 2015 Pharma deals in March 2015

    Two days' later Teva acquired four oncology development programmes (the most advanced in phase I/II) from Ignyta for $42m.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics